The complete response data in a historically checkpoint-refractory population is a notable positive signal for ELI-002 7P's mechanism. However, the data is from only three patients and the Phase 1 study is not yet funded. Monitor for financing announcements and further clinical data updates.
Price Chart
Executive Summary
Elicio Therapeutics hosted a key opinion leader event on June 24, 2026, presenting data on three metastatic PDAC patients who achieved complete radiographic and metabolic responses following ELI-002 7P treatment and subsequent nivolumab-based therapy. The company announced plans for a Phase 1 study evaluating ELI-002 7P in combination with checkpoint inhibition in first-line metastatic PDAC, subject to funding. The data is hypothesis-generating and the study is not yet initiated.
Key Facts
- Three patients with MSS/MMR-proficient metastatic PDAC achieved 100% confirmed complete radiographic and metabolic responses following ELI-002 7P and subsequent nivolumab-based therapy.
- Two of three complete responses were maintained for 9 months, including one ongoing response.
- Complete response rates in historical metastatic PDAC studies range from 0-8% across chemotherapy, checkpoint inhibitor, and targeted therapy regimens.
- Company plans to initiate a Phase 1 study of ELI-002 7P + checkpoint inhibition in 1L mPDAC, subject to funding.
- Initial efficacy signals from the Phase 1 study are expected within 36 months of study start.
Financial Impact
No financial data provided in the filing. The Phase 1 study is subject to funding, indicating potential capital needs.
Risk Factors
- Data is from only three patients and is hypothesis-generating, not prospective.
- Phase 1 study is subject to funding; capital raise may cause dilution.
- Complete responses were achieved with subsequent nivolumab-based therapy, not ELI-002 7P alone.
- No financial data or guidance was provided in this filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001601485-26-000050 |
| Document: angn-20260624.htm | 0001601485-26-000050 |
| Document: 0001601485-26-000050-index-headers.html | 0001601485-26-000050 |
| Document: 0001601485-26-000050-index.html | 0001601485-26-000050 |
| Document: 0001601485-26-000050.txt | 0001601485-26-000050 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 17d ago | DEF 14A | $1.88 | awaiting T+60 | — | $1.70 (−9.57%) |
Sep 22, 2026 4w ago | Institutional Cluster | $1.87 | awaiting T+60 | — | $1.70 (−9.09%) |
Jul 2, 2026 16w ago | 424B5 | $3.22 $1.88 | ▲ +41.61% | ▲ +44.62% | $1.70 (+47.20%) |
Jul 2, 2026 16w ago | 8-K | $3.22 $1.88 | ▲ +41.61% | ▲ +44.62% | $1.70 (+47.20%) |
Jun 24, 2026 17w ago | 8-K | $3.75 $1.89 | ▼ −49.60% | ▼ −53.33% | $1.70 (−54.67%) |
Jun 17, 2026 18w ago | 8-K | $4.71 $2.05 | ▼ −56.48% | ▼ −59.62% | $1.70 (−63.91%) |
May 11, 2026 24w ago | 8-K | $10.55 $3.14 | ▼ −70.24% | ▼ −74.62% | $1.70 (−83.89%) |
Mar 17, 2026 32w ago | EFFECT | $12.18 $14.20 | ▲ +16.58% | ▲ +6.72% | $1.70 (−86.04%) |
Mar 12, 2026 32w ago | Press Release | $12.20 $13.55 | ▲ +11.07% | ▼ −0.55% | $1.70 (−86.07%) |
Mar 2, 2026 34w ago | S-3/A | $12.50 $10.77 | ▲ +13.84% | ▲ +24.16% | $1.70 (+86.40%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers